Doctor's Note — Clinical Trial Summary

Generated by FindMyCure.ai on November 25, 2026 | For discussion with your oncologist

TRIAL

A Study of LN-144 in People With Metastatic Melanoma to the Brain

NCT ID: NCT05640193 Phase: PHASE1 Sponsor: Memorial Sloan Kettering Cancer Center Status: Active Not Recruiting

SUMMARY

This is an open label study evaluating lifileucel (LN-144) in patients with melanoma brain metastases.

KEY ELIGIBILITY CRITERIA

- 1. Metastatic melanoma with asymptomatic brain metastases
- 2. At least one resectable lesion (or aggregate of lesions resected) of a minimum 1.5 cm in diameter post-resection to generate TIL
- 3. Must be e 18 years of age at time of consent
- 4. ECOG performance status of 0-1 and estimated life expectancy of e 3 months
- 5. Adequate hematologic parameters and organ function
- 1. Received organ allograft, except kidney transplant, or prior cell transfer therapy including TIL and CAR-T therapies
- 2. Ongoing grade 2-4 toxicity from prior immunotherapy (excluding endocrine, ocular toxicity or vitiligo)
- 3. History of hypersensitivity to any component or excipient of lifileucel or other treatment regimen drugs
- 4. Symptomatic brain metastases
- 5. Chronic systemic steroid therapy of \> 10 mg/day

Total sites: 1 | 0 currently recruiting

This document is for informational purposes only and does not constitute medical advice. Always discuss clinical trial decisions with your oncologist. Data sourced from ClinicalTrials.gov (NCT05640193) and public sources. Generated by FindMyCure.ai.